BMS-833923 + carboplatin + etoposide

BMS-833923 + carboplatin + etoposide is a combination regimen designed for cancer therapy, specifically evaluated in extensive-stage small cell lung cancer (SCLC)[3]. - BMS-833923 is an oral, small molecule antagonist of the Hedgehog (HH) signaling pathway, targeting the membrane protein Smoothened (SMO), and was developed to inhibit tumor growth by suppressing HH pathway activation[1][2][4]. - Carboplatin is a platinum-based chemotherapy agent that induces DNA damage, leading to cell death. - Etoposide is a topoisomerase II inhibitor that prevents DNA replication, promoting apoptosis in cancer cells. This combination was tested in clinical trials to determine synergistic effects in treating SCLC, and typically involves initial concomitant administration followed by BMS-833923 monotherapy[3].